Trial ID or NCT#
NCT01395758
Status
Purpose
The purpose of this study is to evaluate progression-free survival among subjects with KRAS mutation positive Non-Small Cell Lung Cancer (NSCLC) treated with erlotinib plus tivantinib (ARQ 197) compared to single agent chemotherapy.
Official Title
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
Kavitha Ramchandran
Medical oncologist,
Palliative medicine doctor,
Thoracic specialist,
Internal medicine doctor
Clinical Associate Professor, Medicine - Oncology
A. Dimitrios Colevas, MD
Medical oncologist,
Head and neck specialist,
Cutaneous oncology specialist
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)
Rajat Rohatgi
Joel Neal, MD, PhD
Medical oncologist,
Thoracic specialist
Associate Professor of Medicine (Oncology)
Contact us to find out if this trial is right for you.
CONTACT
Cancer Clinical Trials Office
(650) 498-7061
View on ClinicalTrials.gov